Renasant Bio

Operator of a biopharmaceutical research platform intended to develop oral small-molecule therapies for genetic kidney disorders. The company’s platform advances corrector and potentiator programs that target the underlying biology of autosomal dominant polycystic kidney disease, enabling nephrologists, healthcare providers, and patients with disease-modifying treatment options.